Verrica Q2 FY26 net loss widens to $13.2 million; revenue drops 53.85% to $5.9 million
VRCA•Q2 revenue and loss
Verrica posted Q2 2026 revenue of $5.9 million, down from $12.7 million a year earlier, while net loss widened to $13.2 million.
YCANTH revenue and pipeline updates
U.S. YCANTH net product revenue rose 12.3% year over year to $5.1 million, driven by higher deliveries to distribution partners.
License and collaboration revenue fell to $769,000 from $8.2 million, as the prior-year quarter included an $8 million one-time milestone.
YCANTH dispensed applicator units climbed 28.3% from the prior quarter to 19,626, up 46.1% year over year.
Topline data from the global Phase 3 common warts program is expected in mid-2027; a new $27.5 million credit facility could extend cash runway into 2028.
